On the stock market since 2019, it operates in the world of health and science. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades below its recent peak — about 10% off the top. A pullback, not a collapse.
The company sells $3.5B a year; the problem isn’t sales — it’s costs running above that number.
It pays out $7.49 per share each year — regular cash for whoever holds the stock.
A loss of $154.6M against $3.5B in annual sales.
At the current pace of spending, the cash lasts about 1.6 years. After that, the company needs to find new money.
On our five-subject report card, CHNGU sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: CHNGU has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.